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Abstract
The generalisability of randomised controlled trials will be compromised if markers of treatment outcome also affect trial recruitment. In
a large trial of chronic widespread pain, we aimed to determine the extent to which randomised participants represented eligible
patients, and whether factors predicting randomisation also influenced trial outcome. Adults from 8 UK general practices were
surveyed to determine eligibility for a trial of 2 interventions (exercise and cognitive behavioural therapy [CBT]). Amongst those eligible,
logistic regression identified factors associatedwith reaching the randomisation step in the recruitment process. Themain trial analysis
was recomputed,weighting for the inverse of the likelihood of reaching the randomisation stage, and the numbers needed to treatwere
calculated for each treatment. Eight hundred eighty-four persons were identified as eligible for the trial, of whom 442 (50%) were
randomised. Several factors were associated with the likelihood of reaching the randomisation stage: higher body mass index (odds
ratio: 1.99; 0.85-4.61); more severe/disabling pain (1.90; 1.21-2.97); having a treatment preference (2.11; 1.48-3.00); and expressing
positivity about interventions offered (exercise: 2.66; 1.95-3.62; CBT: 3.20; 2.15-4.76). Adjusting for this selection bias decreased the
treatment effect associated with exercise and CBT but increased that observed for combined therapy. All were associated with
changes in numbers needed to treat. This has important implications for the design and interpretation of pain trials generally.
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1. Introduction
Randomised controlled trials (RCTs) remain the gold standard for
assessing the efficacy and effectiveness of interventions. However,
typically, they are conducted with highly selected patient pop-
ulations and the results then generalised to wider patient
populations.9 The appropriateness of this generalisation is based,
at least in part, on the extent to which the randomised patients
resemble the entire eligible patient population, and the belief that
the biological effect will be the same in other populations. A
concern with the external validity of trials (including those
concerned with pain) has led to renewed interest in “Real World
Evidence” (ie, observational data) as perhaps providing more
appropriate evidence on treatment effectiveness in settings in
which they may be typically applied.12
These assumptions may not hold true. It is known that certain
population groups are, generally, more willing to be randomised
than others–these include the less well educated6,11 and those
with more severe symptoms2,6—and the generalisability of trial
results may be compromised if certain patient characteristics that
are associated with trial recruitment are also markers of the trial
treatment outcome. However, the extent to which this is the case
for individual trials is often impossible to gauge, as trial recruitment
frequently occurs in such a way that detailed information on
eligible but nonrandomised patients is not available.
Recent reviews and meta-analyses have shown that eligible
individuals may be less likely to enter a trial if they have strong
treatment preferences.10,16 In addition, treatment preference may
be associated with prognostic indicators in trial participants, such
as anxiety,15 and symptomseverity.2,10 There is also evidence that,
among trial participants, treatment effect differs according to
a priori treatment preferences.10,16
We conducted an RCT of the management of chronic
widespread pain in primary care–the MUSICIAN study (Managing
Unexplained Symptoms In primary Care: Involving traditional and
Accessible New approaches).13 The trial was a factorial 2 3 2
design and interventions were (1) prescribed exercise delivered
by trained fitness instructors, and including access to a fitness
facility; (2) cognitive behavioural therapy (CBT) delivered over the
telephone by trained therapists; (3) both of the above; or (4) usual
care. We found that both exercise and CBT were associated with
important and statistically significant improvements in patient
global assessment in both the medium and long terms,
although no additional benefit was gained from receiving both
treatments.1,13 Trial patients were identified using a large
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population-based survey. This gave rise to a unique opportunity
to gather detailed information from a large pool of eligible
individuals; to characterise those who did and those who did
not consent to randomisation; and to determine the influence of
treatment preference on the likelihood that an eligible individual
would be randomised.
Thus, using data from the MUSICIAN study, the aims of the
current study were, firstly, to examine factors that may affect the
generalisability of trial results and secondly, to examine the extent
to which external validity may be compromised, by determining
whether factors predicting randomisation also influenced trial
outcome.
2. Methods
The MUSICIAN study was a 23 2 factorial RCT investigating the
management of chronic widespread pain (registration number:
ISRCTN67013851), the methods and main results (including
CONSORT statement) of which have been described else-
where.1,13,14 In brief, potential trial participants were identified by
means of a large-scale postal questionnaire survey, mailed to all
45,994 individuals aged 25 years and older registered with 8
general practitioners in the city of Aberdeen, Scotland, and North
Cheshire, England. As over 95% of UK residents are registered at
a GP practice, and these practices were located in areas of
varying levels of socioeconomic status, this was considered to be
suitably representative of the general population. Questionnaire
respondents were potentially eligible to be randomised if they
reported:
(1) Pain consistent with the American College of Rheumatology
definition of chronic widespread pain in their 1990 classifica-
tion criteria for fibromyalgia20;
(2) Pain of some impact, defined as a score of$1 on the Chronic
Pain Grade19; and
(3) Pain for which they had consulted their general practitioner at
least once, within the previous 12 months.
In addition, trial inclusion criteria required patients to consent to
be contacted again, and to have:
(4) No health condition identified as requiring an alternative
treatment;
(5) Access to a land-line telephone; and
(6) No contra-indications to exercise. (Note: pain alone was not
considered a contra-indication.)
The questionnaire provided brief information about the
exercise and CBT treatments offered in the trial (although, at this
stage, participants did not know that they might be invited to take
part in a trial). It also elicited information about participants’
familiarity with these treatments; how positive they would be
about receiving the treatments (using a 0-10 visual analogue
scale); and how effective they believed they would be, were they
to receive them (on a 5 point Likert scale from “much improved,”
to “much worse”). Treatment preference was assessed by
a single question asking participants which of the available
treatments they would opt for, were they to have been given
a choice.
Survey respondents who were potentially eligible for the RCT
were thenmailed information about the trial itself, after which they
were contacted by a research nurse to confirm eligibility and
arrange an initial assessment appointment in a local clinical
research facility. At this appointment if eligibility was confirmed
and consent was obtained, randomisation took place.
The primary outcome for the trial was a 7-point, patient global
impression change score, assessed by self-completion ques-
tionnaire, at 6 and 9 months post-randomisation. Patients were
asked to rate how they felt their health had changed since the
period before entering the trial, ranging from 1 (“very much
worse”) to 7 (“very much better”). Questionnaire nonrespondents
were asked the same question verbally, by telephone interview.
2.1. Analysis
Firstly, amongst individuals surveyed, responders and non-
responders were compared and among survey respondents
eligible for randomisation, differences were examined between
those individuals who were/were not subsequently randomised.
This was done using x2 tests and nonparametric tests for trend5
and the magnitude of any differences characterised using logistic
regression. Thus, differences are expressed as odds ratios with
95% confidence intervals (95% Confidence interval (CI)). Sec-
ondly, a forward stepwise regression model was constructed, to
identify which variables independently predicted randomisation. If
not already dichotomous, these variables were then dichoto-
mized and N3 2 categories were created, where N represented
the number of factors in the multivariable regression model. The
primary trial analysis (presented elsewhere13) was then recom-
puted, weighting for the inverse of the likelihood of randomisation
(ie, likelihood of reaching randomisation stage), for every given
combination of N 3 2 categories. Finally, the number needed to
treat (NNT) was calculated for each of the treatments, based on
the weighted odds ratios.
Statistical analysis was conducted using STATA 11.1 from
STATACORP, Texas. Numbers needed to treat were calculated
in Microsoft Excel, using published formula.3
3. Results
Of 45,994 individuals invited to participate in the survey, useable
questionnaire responses were received from 15,313 (33%).
Women were significantly more likely to respond than men
(37% vs 29%; x25 328.1, P, 0.001) and there was a significant
increase in response rate with age (21% among those aged 25-
40 years, increasing to 45% in those .60 years; nonparametric
test for trend P, 0.001). Of the 15,313 responders, 1844 (12%)
reported chronic widespread pain of whom 884 (48%) were
eligible to take part in the trial and 442 (50%) were eventually
randomised. Of the 442 responders not randomised, 94 were
subsequently found to be ineligible, and one died before they
attended the screening visit. Thus, there were 347 participants
who met all trial inclusion criteria, but were not randomised. The
flow of participants from initial survey invitation to subsequent
randomisation is shown in Figure 1.
The median age of eligible participants was 57 years (inter-
quartile range: 46-66 years) and 68% were females. Two-thirds
(67%) rated their health as “good,” or better; 28% had a body
mass index .30 kg/m2; and 51% were ex-smokers or current
smokers. Of the eligible survey participants, those aged 41 to 60
years were significantly more likely to be randomised than
younger respondents (odds ratio: 1.54; 95% confidence interval:
1.02-2.33). However, this effect was not linear and there was no
further increase in the likelihood of randomisation among those
aged .60 years (1.31; 0.87-1.98). Also, there was no difference
in the likelihood of randomisation between men and women
(odds ratio for women: 1.23; 0.91-1.66).
A significant trend existed, such that participants with higher
BMI (P 5 0.03) and higher Chronic Pain Grade (signifying more
severe and/or disabling pain) (P 5 0.002) were more likely to be
randomised than other individuals (Table 1). Participants already
taking some exercise (1-2 times/wk) were more likely to be
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randomised in comparison with those not currently exercising,
but those undertaking frequent exercise (.5 times/wk) were not
more likely to be randomised than those not exercising.
Participants with a treatment preference were twice as likely to
be randomised as those without (2.11; 1.48-3.00), and this effect
existed irrespective of whether the preference was for exercise,
CBT, or both (Table 2). Positivity about receiving either exercise
(2.66; 1.95-3.62) or CBT (3.20; 2.15-4.76) was associated with
an increase in the likelihood of randomisation, although no such
effect was observedwith participant expectations of outcome, for
either treatment (Table 2).
Five factors were found to be independently associated with
randomisation (ie, reaching the randomisation step in the
recruitment process): age, positivity about exercise, positivity
about CBT, more severe disabling Chronic Pain Grade, and
taking regular exercise. Weighting the analysis by the inverse of
the likelihood of randomisation (essentially, simulating the effect
of all eligible nonparticipants actually being randomised) resulted
in slight difference in the treatment effect estimates at both 6 and
9 months. For the single therapies, at 6 months, the weighted
model resulted in an 11%decrease in themagnitude of treatment
effect for CBT (from an odds ratio of 6.45; 2.42-17.2 to 5.72;
1.92-17.0) and a 25% decrease in the treatment effect
associated with exercise (from 7.28; 2.79-19.0 to 5.49; 1.89-
16.0). In contrast, the weightedmodel gave a 16% increase in the
estimate of treatment effect of the combined therapy (Table 3).
The same pattern was true at 9 months, although the magnitude
of the changes in effect estimates was less (5% decrease, 11%
decrease, and 19% increase, respectively). For CBT, the
weighted model produced no change in the number needed to
treat. However, for exercise, there was an increase in the NNT
from 4 to 5, for improvement at 6 months, and from 7 to 8 for
improvement at 9 months. For the combined therapy, NNT fell
from 5 to 4 for improvement at 9 months.
4. Discussion
In the context of a large randomised controlled trial examining the
effectiveness of exercise therapy and CBT for chronic wide-
spread musculoskeletal pain, we have shown that individuals
who were randomised were different, in a number of ways, from
the entire eligible patient population that was originally identified.
Randomised individuals had a higher BMI, and more severe and/
or disabling pain. They were also more likely to have a treatment
preference, for either or both of available trial treatments, and be
more positive about receiving either of the treatments available in
the trial. We have demonstrated that this selection bias resulted in
a change in treatment effect estimation, and in the associated
NNT, although the changes noted were modest.
The design of the MUSICIAN study and, specifically, the
opportunity to collect a large amount of data on individuals
who were eligible to participate in the trial, but who were not
ultimately randomised, allowed an assessment of potential
selection bias which is rare in trials. This notwithstanding, there
are a number of methodological issues to discuss, in
interpreting these findings. The first issue is the timing of data
collection. All predictors of randomisation were collected by
population survey typically 1 to 2 weeks before randomisation.
Although this has the advantage that participants completed
these questions naı¨ve to their eligibility for the trial, it may be
that participants report different treatment preferences,
positivity and expectations in what they believe to be
a hypothetical situation, than they would if actually faced with
the possibility of receiving either therapy. Secondly, only one-
Figure 1. Flow of participants in the study.
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third of the survey questionnaires were returned. Population
survey questionnaire response rates are falling over time8 and
participation rates of 33% are not uncommon. The current
study aimed to determine whether trial participants were
different from eligible but nonrandomised participants. By
definition, individuals who failed to complete the initial survey
questionnaire were not eligible for the trial. This study looked at
how refusal to participate after the identification of eligible
patients affected representativeness; a separate source of
selection bias (not under examination in the current study)
comes from not being able to identify eligible patients in the
first place. Although the prevalence of chronic widespread
pain in the current study was very similar to other large
population studies,14 we know that responders and
nonresponders differ with respect to age and gender. The
differences were 24% and 8.0%, respectively, with older
individuals and women significantly more likely to respond than
other individuals, and among all respondents, these individ-
uals were also significantly more likely to be randomised. This
illustrates further that trial participants are different from the
wider eligible patient population.
Our findings concur with other studies which have shown
that trial participants differ from the wider eligible population in
a number of ways and that participants with severe or
disabling pain were more likely to be randomised is perhaps
no surprise. These individuals may be more willing than other
participants to try novel or hard-to-access treatments. It is
also plausible that those with a higher BMI may have been
more willing to enter the trial, to benefit (potentially) from the
exercise therapy. What is particularly pertinent, however, is
not why randomised and nonrandomised participants are
different, but the fact that they are different with respect to
a number of important prognostic markers. Increasing the
likelihood that persons agree to take part in trials for which
they are eligible is key to reducing this selection bias. A
systematic review of factors which could potentially increase
the chance of an approached person agreeing to take part in
a trial for which they are eligible showed the following to be
effective: strategies to increase awareness of the health
problem being studied (including an interactive computer
programme, education session, or video about the health
problem being studied). In contrast increasing patients’
Table 1
Differences in demographics and health, between eligible survey participants who were/were not randomised.
Randomised Odds ratio (95% CI) for randomisation
Yes No Crude Age adjusted
Age, y
25-40 61 64 1.00 —
41-60 197 134 1.54 (1.02-2.33) —
.60 184 147 1.31 (0.87-1.98) —
Gender
Male 135 120 1.00 1.00
Female 307 225 1.21 (0.90-1.64) 1.23 (0.91-1.66)
Self-rated health
Excellent 7 10 1.00 1.00
Very good 76 63 1.72 (0.62-4.79) 1.70 (0.61-5.47)
Good 210 158 1.90 (0.71-5.10) 1.84 (0.68-4.96)
Fair 127 96 1.89 (0.69-5.15) 1.82 (0.66-4.98)
Poor 20 16 1.79 (0.55-5.74) 1.71 (0.53-5.54)
BMI, kg/m2
#20 15 15 1.00 1.00
20.1-25.0 133 119 1.13 (0.53-2.40) 1.10 (0.51-2.36)
25.1-30.0 157 128 1.23 (0.58-2.60) 1.16 (0.54-2.49)
30.1-35.0 74 53 1.40 (0.63-3.10) 1.30 (0.58-2.91)
.35.0 62 31 2.00 (0.87-4.61) 1.99 (0.85-4.61)*
Smoking status
Never 219 161 1.00 1.00
Ex-smoker 154 111 1.02 (0.74-1.40) 1.02 (0.74-1.40)
Current smoker 63 67 0.69 (0.46-1.03) 0.70 (0.47-1.05)
Regular exercise†
None 84 82 1.00 1.00
1-2 times per week 177 113 1.53 (1.04-2.25) 1.55 (1.05-2.28)
3-4 times per week 100 75 1.30 (0.85-1.99) 1.33 (0.86-2.04)
$5 times per week 79 72 1.07 (0.69-1.66) 1.08 (0.69-1.69)
Chronic Pain Grade‡
I 86 100 1.00 1.00
II 152 117 1.51 (1.04-2.20) 1.53 (1.05-2.23)
III 85 53 1.86 (1.19-2.92) 1.90 (1.21-2.99)
IV 86 53 1.89 (1.21-2.95) 1.90 (1.21-2.97)§
* Test for trend across categories P 5 0.03.
† Number of times per week doing 30minutes of moderate physical activity or walking that increased the heart rate or increased breathing.
‡ Due to trial eligibility criteria, there were no participants with a Chronic Pain Grade 5 0.
§ Test for trend across categories P 5 0.002.
BMI, body mass index; CI, confidence interval.
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understanding of the trial process, recruiter differences, and
various methods of randomisation and consent design were
not associated with improved recruitment.4
Our findings also show that eligible individualswith a preference
for one or both of the investigative treatments in the MUSICIAN
trial were more likely to be randomised than those with no
preference. This is likely to be at least partially explained by the
nature of the interventions offered in the MUSICIAN trial. In the
UK, neither prescribed exercise (including free gym membership
for 6 months, and complimentary access to a fitness instructor)
nor CBT are routinely available for chronic widespread pain in
primary care. Previous trials have reported that a strong treatment
preference was a key reason for refusing randomisation7,10,17,18
and this also has important implications for the generalisability of
findings. A recent meta-analysis of 11 musculoskeletal trials
found that, among participants, treatment preference was an
important determinant of outcome.16
We have also shown that the factors that influence whether
a potential participant is likely to be randomised into a trial also
influence trial outcome. Re-computing the main trial analysis,
to adjust for the fact that the randomised participants are
different from the total eligible patient population, gave
intriguing findings. For the single therapies, our weighted
model resulted in a decrease in treatment effect, suggesting
that any selection bias (in the original analysis) acted to
overestimate treatment effects. Whereas, for combined ther-
apy, the opposite was true, suggesting that any selection bias
led to an underestimate of the effect of treatment. In the context
of the current trial, where the treatment effect sizes were large
(ORrange: 6.45-7.28 at 6 months, and 3.41-5.57 at 9 months)
Table 3
The influence of factors associated with randomisation, on trial outcome.
Treatment group Improvement* at 6 mo post randomisation,
odds ratio (95% CI) [NNT]
Improvement* at 9 mo post randomisation,
odds ratio (95%CI) [NNT]
Original findings† Weighted model Original findings† Weighted model
Treatment as usual 1.00 1.00 1.00 1.00
CBT 6.45 (2.42-17.2) [NNT 5 4] 5.72 (1.92-17.0) [NNT 5 4] 5.57 (2.34-13.3) [NNT 5 5] 5.31 (2.06-13.7) [NNT 5 5]
Exercise 7.28 (2.79-19.0) [NNT 5 4] 5.49 (1.89-16.0) [NNT 5 5] 3.41 (1.42-8.15) [NNT 5 7] 3.02 (1.18-7.76) [NNT 5 8]
CBT 1 Exercise 6.76 (2.56-17.8) [NNT 5 4] 7.86 (2.69-23.0) [NNT 5 4] 5.18 (2.19-12.3) [NNT 5 5] 6.19 (2.41-15.9) [NNT 5 4]
* “Much better” or “very much better” on patient global change score on how patients felt their health had changed since entering the trial, from 1 (“very much worse”) to 7 (“very much better”).
† Effect estimates and NNTs differ slightly from those in the original manuscript 7 because we have excluded individuals with missing values for variables used in the weighting calculation.
NNT, numbers needed to treat; CBT, cognitive behavioural therapy; CI, confidence interval.
Table 2
Differences in treatment preference and expectation, between eligible survey participants who were/were not randomised.
Randomised Odds ratio (95% CI) for randomisation
Yes No Crude Age adjusted
Treatment preference
No* 68 95 1.00 1.00
Yes 362 245 2.06 (1.45-2.93) 2.11 (1.48-3.00)
Treatment preference
None* 68 95 1.00 1.00
Exercise 170 151 1.57 (1.07-2.30) 1.60 (1.09-2.34)
CBT 27 16 2.36 (1.18-4.71) 2.38 (1.18-4.76)
Both treatments 165 78 2.96 (1.96-4.46) 2.10 (2.04-4.70)
Expectations of exercise†
Improve 347 236 1.00 1.00
No change 58 64 1.62 (1.10-2.40) 1.67 (1.12-2.48)
Worsen 21 17 1.36 (0.66-2.83) 1.34 (0.64-2.79)
Expectations of CBT†
Improve 228 129 1.00 1.00
No change 175 168 1.70 (1.25-2.30) 1.74 (1.28-2.37)
Worsen 3 5 0.58 (0.14-2.45) 0.55 (0.13-2.33)
Positivity re: exercise‡§
Low 113 159 1.00 1.00
Moderate/high 325 182 2.51 (1.86-3.40) 2.66 (1.95-3.62)
Positivity re: CBT‡
Low 125 154 1.00 1.00
Moderate 165 116 1.75 (1.25-2.45) 1.85 (1.31-2.60)
High 141 60 2.90 (1.97-4.25) 3.20 (2.15-4.76)
* Includes participants with no preference, and those who responded “don’t know.”
† The imagined effect of 6 months of treatment, on participants’ chronic pain.
‡ How positive participants would be about receiving the treatment, one a 0 to 10 scale; divided into tertiles for analysis.
§ Due to the skewed distribution of positivity regarding exercise, the moderate and high tertiles form one category.
CBT, cognitive behavioural therapy; CI, confidence interval.
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an over- or under-estimate of the magnitude observed in the
current study makes little difference to the overall conclusions
of the trial. However, many trials have smaller effect sizes and,
while it is impossible to predict what the results would be, over-
or under-estimates of between 10% and 24% may have
important implications in interpretation of trial findings. As in the
current study, even minor changes in effect size, may result in
changes in NNT, and this may have potentially important
implications for estimates of the cost-effectiveness of treat-
ments. In the original MUSICIAN trial for the primary outcome14
exercise was not cost effective, and the cost effectiveness of
CBT was marginal. In this context, even minor errors in
estimation of effect measures are important.
In summary, the status of randomised controlled trials as the
gold standard method for determining the effectiveness of
healthcare interventions is based on their inherent internal validity
and the ability to control potential confounding variables, but they
are commonly conducted on highly selected patient groups.
Their real world value, therefore, depends on the assumption that
these patient groups adequately represent the entire eligible
patient population, yet rarely is information available to test this
assumption. Capitalising on a unique opportunity to collect data
on a wider eligible population we have shown, firstly, that trial
participants differ not only in terms of clinical variables, but also in
terms of treatment preference; and, secondly, that the factors
associated with trial participation also influence trial outcome.
This has important implications for trials generally and empha-
sises that, where possible, collecting information on eligible but
nonrandomised patients allows a better estimate of treatment
effectiveness.
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